Drug Trial Radar · NCT00300430
Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.
Last checked: Nov 20, 2026Latest source record: Jul 23, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,911
Actual
Start
Sep 2006
Primary completion
Mar 2008
Sponsor
- Lead sponsor
- AbbottIndustry
- Sponsor type
- Industry
- First posted
- Mar 9, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to test the safety and the effects of using an investigational drug regimen; once daily ABT-335 (Investigational drug) administered in combination with once daily atorvastatin calcium, rosuvastatin calcium or simvastatin in patients with abnormal lipid levels in the blood.
Conditions
- Dyslipidemia
- Coronary Heart Disease
- Mixed Dyslipidemia
Interventions
ABT-335 and rosuvastatin calciumDrug
ABT-335 135 mg plus rosuvastatin calcium daily, 52 weeks
ABT-335 and atorvastatin calciumDrug
ABT-335 135 mg plus atorvastatin calcium daily, 52 weeks
ABT-335 and simvastatinDrug
ABT-335 135 mg plus simvastatin daily, 52 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects Reporting Adverse Events During Combination Therapy, Either in the Preceding Double-blind Studies or in This Open-label StudyTime frame: Anytime after initiation of combination therapy (either in the double-blind or open-label study) to within 30 days after the last dose of combination therapy
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Global Medical Information
North Chicago, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.